Fundraising Fox

Bonum Therapeutics

Seattle, US · Founded 2021 · Delaware corporation · 4 known investors

bonumtx.com ↗

Bonum Therapeutics is an early-stage biotechnology company. This page profiles a board member's background in drug development and life sciences investing rather than describing the company's specific products.

Biotechin /bonum-therapeutics

Founders & leadership

SB
Samuel BjorkDirector
NP
Neela PatelExecutive Officer
DH
Diane HollenbaughExecutive Officer
SB
Samuel BlackmanDirector
JM
John MulliganExecutive Officer, Director, Promoter
KH
Karl HandelsmanDirector
NW
Nicholas WalrodDirector
MM
Mitchell MutzDirector
GA
Gaurav AggarwalDirector
MS
Monique SchiersingDirector
JM
John McKearnDirector

Investors · 4

RiverVest Venture PartnersSt. Louis · $500K – $3Mvia John McKearn · board
Roche Venture FundBasel · $648K – $3.2M
Vivo CapitalPalo Alto · $10M – $50M
Digitalis VenturesreportedNew York · $100K – $10M

Reported raises · per SEC filings

Form D private placements
▶$26.9MraisedApr 2026 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Samuel BjorkDirector
  • Monique SchiersingDirector
  • Neela PatelExecutive Officer
  • John McKearnDirector
  • Diane HollenbaughExecutive Officer
  • Samuel BlackmanDirector
  • John MulliganExecutive Officer, Director, Promoter
  • Karl HandelsmanDirector
  • Nicholas WalrodDirector
  • Mitchell MutzDirector
  • Gaurav AggarwalDirector
Offering amount
$32.3M
Amount sold
$26.9M
First sale
Apr 2026
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$45MraisedNov 2022 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Karl HandelsmanDirector
  • John MulliganExecutive Officer, Director, Promoter
  • Nicholas WalrodDirector
  • Monique SchiersingDirector
  • John McKearnDirector
  • Samuel BjorkDirector
  • Diane HollenbaughExecutive Officer
  • Neela PatelExecutive Officer
  • Mitchell MutzDirector
Offering amount
$93M
Amount sold
$45M
First sale
Nov 2022
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.2MraisedDec 2021 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Karl HandelsmanDirector
  • Diane HollenbaughExecutive Officer
  • Neela PatelExecutive Officer
  • John McKearnDirector
  • Monique SchiersingDirector
  • Nicholas WalrodDirector
  • John MulliganExecutive Officer, Director, Promoter
Offering amount
$3.6M
Amount sold
$1.2M
First sale
Dec 2021
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.